Biggest Medical Device M&A Deals of 2025-2026: Complete Tracker

Medtech M&A Has Entered a New Era

The medical device industry is experiencing one of its most active M&A cycles in history. After a post-pandemic trough in 2023 when deal activity bottomed out at approximately $39 billion, medtech M&A rebounded sharply in 2024 (~$68 billion) and then surged in 2025 to over $80 billion in total disclosed deal value. The first quarter of 2026 alone has already exceeded $40 billion in announced transactions, putting the year on pace for $80-100 billion (MassDevice; Bain & Company; Xtalks).

This is not a broad-based buying frenzy. The 2025-2026 deal environment is defined by three clear patterns:

1. Portfolio reshaping — Large conglomerates are spinning off or divesting underperforming divisions to concentrate capital on high-growth segments
2. Cardiovascular dominance — Cardiovascular and neurovascular devices account for a disproportionate share of deal value, driven by strong reimbursement and procedure volume growth
3. Private equity's growing footprint — PE firms are executing the largest take-privates in medtech history, capitalizing on softer valuations and record dry powder

According to an EY report analyzing July 2024 through June 2025, overall M&A deal volume declined 41% to 61 medtech mergers — but the average deal size ballooned to $636 million, confirming that capital is concentrating around fewer, larger, higher-conviction bets (MedTech Dive).

The Biggest Medtech M&A Deals: 2025

The following table tracks every disclosed medtech transaction exceeding $500 million announced in 2025, ranked by deal value.

Sources: MassDevice Medtech M&A Roundup 2025; MPO Magazine 2025 M&A Roundup; Xtalks.

The Biggest Medtech M&A Deals: 2026 (Year-to-Date)

2026 opened with blockbuster deal activity. These are the major transactions announced so far.

Sources: Danaher Investor Relations; MPO Magazine 2026 M&A Roundup; Xtalks MedTech M&A 2026 Tracker.

Deal-by-Deal Analysis: The Mega-Deals

Abbott / Exact Sciences — $21 Billion

The largest medtech M&A deal of 2025 and one of the ten largest in medtech history. Abbott is acquiring Madison, Wisconsin-based Exact Sciences, the maker of Cologuard, a non-invasive colorectal cancer screening test that allows patients to screen at home by collecting a stool sample and mailing it to a lab. Exact Sciences generates approximately $3 billion in annual revenue and has built one of the strongest consumer-facing diagnostics brands in the industry.

Strategic rationale: Abbott's diagnostics segment was down 5% in the first nine months of 2025. Exact Sciences delivers both scale and strategic reinforcement — adding a high-growth cancer screening platform that complements Abbott's existing diagnostics capabilities. The deal values Exact Sciences at approximately $23 billion on an enterprise value basis (MassDevice; Life Science Market Research).

Regulatory note: Expected to close in Q2 2026 subject to regulatory approvals and customary closing conditions.

Blackstone & TPG / Hologic — $18.3 Billion Take-Private

The largest medtech take-private transaction on record. PE firms Blackstone and TPG agreed in October 2025 to acquire Hologic, a leader in women's health diagnostics and breast health solutions, at $76 per share in cash. Shareholders also receive a contingent value right (CVR) of up to $3 per share tied to global revenue targets in Hologic's breast health business for fiscal years 2026 and 2027 (MassDevice; Private Capital Global).

Strategic rationale: Hologic is a well-run, profitable women's health platform with stable revenue streams — exactly the profile that PE firms favor for take-private transactions. The deal signals PE's growing confidence in medtech as an asset class where regulatory barriers to entry, recurring revenue models, and durable procedure volumes create defensible portfolio companies.

Deal structure: All-cash offer plus CVR, with committed financing secured by Blackstone and TPG. Hologic's board unanimously approved the agreement. Expected to close in H1 2026.

BD / Waters — $17.5 Billion Reverse Morris Trust

BD announced in July 2025 that it would combine its Biosciences & Diagnostic Solutions business with Waters Corporation in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. This follows BD's February 2025 announcement of its plan to sell the Life Sciences business, part of a broader portfolio simplification strategy (MassDevice; MPO Magazine).

Strategic rationale: BD is shedding non-core assets to concentrate on its core medical delivery and intervention businesses. Waters gains BD's biologics expertise and regulatory presence in clinical and diagnostics settings, expanding its bioseparations portfolio.

Boston Scientific / Penumbra — $14.5 Billion

The largest deal announced in 2026 so far. Boston Scientific agreed in January 2026 to acquire Alameda, California-based Penumbra for $374 per share ($14.5 billion enterprise value). Penumbra is a major provider of mechanical thrombectomy products for peripheral vascular procedures (Intellizence; Xtalks).

Strategic rationale: The deal significantly expands Boston Scientific's neurovascular and interventional device portfolio, reinforcing its leadership in minimally invasive therapies. Cardiovascular remains the center of gravity for medtech M&A — this acquisition represents "a doubling down on high-growth interventional capability" rather than a diversification play (ZS Medtech Trends 2026).

Danaher / Masimo — $9.9 Billion

Announced February 17, 2026, Danaher agreed to acquire Masimo Corporation, a specialist in pulse oximetry and non-invasive patient monitoring, for $180 per share in an all-cash deal. The total enterprise value is approximately $9.9 billion including assumed indebtedness and net of acquired cash (Danaher Investor Relations; Reuters).

Key financial details:

Source: Danaher Investor Relations press release, Feb 17, 2026.

Masimo will operate as a standalone company within Danaher's Diagnostics segment alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Masimo generated approximately $1.5 billion in revenue in 2025, with Q4 revenue of $411 million growing 12% year-over-year (Fierce Biotech; Healthcare Digital).

Stryker / Inari Medical — $4.9 Billion

Orthopedic giant Stryker announced the acquisition of Inari Medical in January 2025 at $80 per share ($4.9 billion), closing the deal in February 2025. Inari develops solutions for venous thromboembolism (VTE) clot removal without thrombolytic drugs, including the FlowTriever system for pulmonary embolism and ClotTriever for peripheral vessel thrombectomy (Stryker; MassDevice).

Strategic rationale: The acquisition gave Stryker an established peripheral vascular position in the high-growth VTE segment. Stryker subsequently renamed its Neurovascular business unit to "Vascular" to reflect the expanded scope. In Q3 2025, the Vascular segment generated $539 million in revenue, growing 58.1% year-over-year on a reported basis (Stryker Q3 2025 earnings).

Deal That Didn't Close: Alcon / STAAR Surgical

Not every deal makes it to the finish line. Alcon agreed to acquire STAAR Surgical in August 2025 for $1.5 billion ($28 per share), later raising the offer to $1.6 billion ($30.75 per share) in December 2025. STAAR makes the EVO Implantable Collamer Lens for myopia correction (MPO Magazine; MedTech Dive).

Broadwood Partners, STAAR's largest shareholder with a 30.2% stake, opposed the deal from the start, arguing the price undervalued the company — noting that Alcon had previously offered $55 per share in October 2024. Despite a 30-day "go-shop" window, no superior proposal materialized. STAAR shareholders voted against the merger on January 6, 2026, and the merger agreement was terminated with no termination fee payable by either party.

The aftermath was significant: CEO Stephen Farrell and Chair Elizabeth Yeu resigned, and STAAR named interim co-CEOs while searching for permanent leadership (MedTech Dive; BioWorld).

Lesson for deal-makers: Even in a hot M&A market, shareholder activism can derail transactions — especially when an activist investor holds a blocking stake and argues that an acquirer's offer represents a steep discount to prior valuations.

Key M&A Trends Shaping 2025-2026

1. Portfolio Reshaping Through Divestitures

The most distinctive feature of 2025-2026 medtech M&A is not what companies are buying — it is what they are selling. Large conglomerates are breaking themselves apart to concentrate on faster-growing, higher-margin segments:

• BD is spinning off its Biosciences & Diagnostic Solutions business via the $17.5B Waters combination
• Medtronic has spun off its Diabetes business (MiniMed)
• J&J continues separating and restructuring its MedTech portfolio
• Solventum sold its Purification & Filtration business to Thermo Fisher for $4.1B

As ZS's Medtech Trends 2026 report notes: "Much of the industry is trading pure EBITDA for top-line velocity" — companies are shedding profitable but slow-growing divisions to concentrate capital on differentiated, high-growth technologies.

2. Cardiovascular Dominates Deal Flow

Cardiovascular devices are the clear center of gravity for medtech M&A capital. The pattern is unmistakable:

• Boston Scientific / Penumbra ($14.5B) — neurovascular/interventional
• Stryker / Inari Medical ($4.9B) — peripheral vascular/VTE
• Medtronic / CathWorks ($585M) — AI coronary diagnostics
• Medtronic / Scientia Vascular ($550M) — neurovascular access
• 4C Medical ($175M funding round led by Boston Scientific) — heart valve technology

Strong and reliable reimbursement, expanding indication sets, and procedure volume growth make cardiovascular a preferred investment thesis for both strategic acquirers and financial sponsors.

3. Private Equity at Scale

PE firms are no longer just doing bolt-on acquisitions in medtech — they are executing mega-deals:

• Hologic take-private ($18.3B) by Blackstone & TPG is the largest PE healthcare take-private in years
• PE dry powder in healthcare remains at record levels
• Average medtech deal size is increasing as PE concentrates capital in fewer, larger platforms (EY Medtech Report)

The EY report found that medtech firms are splitting into "haves" and "have-nots" — investors are putting more money into fewer companies. Venture capital investment totaled $8.7 billion from July 2024 to June 2025, a 20% increase year-over-year, but total funding rounds declined 47% to 237 (MedTech Dive).

4. AI and Digital Health as Acquisition Targets

AI-enabled medtech is now a mainstream M&A category:

• Medtronic / CathWorks ($585M) — AI-powered coronary diagnostics; Medtronic had held a minority stake since 2018
• GE HealthCare / Intelerad ($2.3B) — cloud-enabled, AI-powered imaging software
• Danaher / Masimo ($9.9B) — includes AI-enabled monitoring technology

The FDA authorized a record 258 AI/ML-enabled medical devices in 2025, bringing the cumulative total to over 1,300. Strategic acquirers are now buying proven AI assets that are already embedded in clinical workflows (ZS Medtech Trends 2026).

5. FTC Posture Is Evolving

The regulatory environment for M&A has shifted. While the FTC successfully blocked the Edwards Lifesciences / JenaValve transaction — a landmark win — the broader trend under the current administration is toward remedies (divestitures) rather than outright blocking. GTCR's acquisition of Surmodics, for example, required remedies but was not blocked (ZS).

Companies are showing "greater willingness to swing for the fences," as ZS put it, with FTC challenges proving less restrictive than anticipated. Medtronic has publicly signaled "a renewed focus on aggressive capital allocation" and Danaher CEO Rainer Blair stated during Q4 2025 earnings that the M&A environment had become "more constructive" and Danaher's "balance sheet is primed" for sizable transactions.

Annual M&A Value Trend (2020-2026)

Sources: Plante Moran PMCF Medical Technology M&A Pulse Q3 2025; Bain & Company; MassDevice.

What to Watch for the Rest of 2026

Several pending catalysts could reshape the deal landscape in H2 2026:

• Abbott / Exact Sciences close (expected Q2 2026) — The largest medtech deal of this cycle; regulatory clearance will signal how antitrust authorities view diagnostics consolidation
• Hologic take-private close (expected H1 2026) — Will set the benchmark for future PE medtech take-privates
• Danaher / Masimo close (expected H2 2026) — Watch for integration strategy and how Masimo fits alongside Cepheid and Beckman Coulter
• Medtronic capital deployment — Management has signaled aggressive M&A intentions; expect additional mid-to-large acquisitions
• IPO-driven exits — Medline's IPO (reportedly the largest healthcare IPO in five years) and the Medtronic Diabetes spinoff could create liquidity events that feed new deal activity
• Continued divestitures — Watch J&J MedTech and Siemens Healthineers for further portfolio simplification moves

The medtech M&A cycle is not slowing down. With strategic acquirers well capitalized, PE firms holding record dry powder, and a more permissive regulatory environment, 2026 is shaping up as one of the most active deal years in the industry's history.

Frequently Asked Questions

What was the biggest medical device M&A deal in 2025?

Abbott's $21 billion acquisition of Exact Sciences, the maker of the Cologuard colorectal cancer screening test, announced in November 2025. On an enterprise value basis, the deal totals approximately $23 billion.

What is the biggest medtech deal of 2026 so far?

Boston Scientific's $14.5 billion acquisition of Penumbra, announced in January 2026. The deal expands Boston Scientific's neurovascular and interventional thrombectomy portfolio.

How much total M&A deal value was there in medtech in 2025?

Disclosed medtech M&A deal value in 2025 exceeded $80 billion, driven by mega-deals from Abbott, Blackstone/TPG (Hologic), BD/Waters, and Stryker. The actual total is higher when including undisclosed private-market transactions.

Why are so many medtech companies divesting businesses?

Large conglomerates are shedding lower-growth, non-core divisions to concentrate capital and management attention on higher-growth segments — particularly cardiovascular, neurovascular, and AI-enabled technologies. BD, Medtronic, J&J, and Solventum have all executed significant divestitures in 2025-2026.

Is private equity becoming more important in medtech M&A?

Yes. The Blackstone/TPG take-private of Hologic ($18.3 billion) is the most visible example, but PE is broadly more active across medtech. EY reports that average deal sizes are increasing while deal volume is declining, consistent with PE's preference for fewer, larger platform investments.